Abstract
Monoclonal antibody MUC 2-63 recognises neurogenic tumours and has been used successfully for radioimaging human malignant gliomas. We now show that the MUC 2-63 antigen has the same tissue distribution and molecular weight range as the CD44 antigen and confirm the identity of these two molecules in blocking studies using MUC 2-63 and the CD44 anti-framework antibody F10-44-2. Thus not only MUC 2-63 but also other anti-CD44 monoclonal antibodies should prove useful in imaging and, perhaps, therapy of brain tumours.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies / immunology
-
Antibody Specificity
-
Antigens, Neoplasm / analysis*
-
Antigens, Neoplasm / immunology
-
Blotting, Western
-
Carrier Proteins / analysis*
-
Carrier Proteins / immunology
-
Colon / chemistry
-
Flow Cytometry
-
Glioma / chemistry*
-
Humans
-
Hyaluronan Receptors
-
Immunohistochemistry
-
Molecular Weight
-
Receptors, Cell Surface / analysis*
-
Receptors, Cell Surface / immunology
-
Receptors, Lymphocyte Homing / analysis*
-
Receptors, Lymphocyte Homing / immunology
-
Skin / chemistry
-
Thymus Gland / chemistry
Substances
-
Antibodies
-
Antigens, Neoplasm
-
Carrier Proteins
-
Hyaluronan Receptors
-
Receptors, Cell Surface
-
Receptors, Lymphocyte Homing